Lakshmi Myneni, MD
Rheumatology · Mountain View
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
Offices
2 locations · County of San Mateo · 316 clinicians in this group
Hospitals listed: El Camino Health · San Mateo Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Myneni’s office to ask if they take your plan before you enroll.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
- San Mateo Medical CenterSan Mateo, CAAcute Care Hospital · Government - Local · Has an emergency departmentPart of San Mateo County HealthPatients rate it 3 of 5 · 68% would definitely recommend itNo overall ratingNo measure marked better or worse than the national rate
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for San Mateo Medical Center
Behind the star rating — Deaths: 0 better, 2 the same, 0 worse of 2 measures. Safety: 0 better, 2 the same, 0 worse of 2 measures. Readmissions: 0 better, 3 the same, 0 worse of 3 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.34 (0.25 to 2.43) · 45 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.97 (0.48 to 1.47) | No different | Jul 2022 – Jun 2024 |
| Death rate for pneumonia patientsComplications and deaths | 13.9 · 25 cases | None | Jul 2022 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.6 · 258 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.21 (0 to 0.44) · 379 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.26 (0.05 to 0.48) · 381 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.44 (0.82 to 6.05) · 57 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.64 (0.92 to 4.37) · 57 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.53 (0 to 1.76) · 296 cases | No different | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.661 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.8 · 47 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -2.3 · 25 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.6 · 76 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14 (10.4 to 18.9) · 167 cases | No different | Jan 2022 – Dec 2024 |
What patients said (208 patients answered, 15% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 78% |
| Nurses "always" communicated well | 76% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 62% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 77% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 72% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 68% |
| Staff "always" explained possible side effects | 51% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
Original Medicare doctor bills
$549,944
Medicare paid this office $549,944 for 155 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection, romosozumab-aqqg, 1 mg | 24 | $234,403 | None |
| Injection, denosumab, 1 mg | 83 | $157,567 | None |
| Return visit (30+ min) | 110 | $24,178 | $117 |
| Short return visit (20+ min) | 87 | $17,755 | $83 |
| Injection of drug or substance under skin or into muscle | 109 | $6,195 | $14 |
See all 8 services
| Injection, romosozumab-aqqg, 1 mg | 24 | $234,403 | None |
| Injection, denosumab, 1 mg | 83 | $157,567 | None |
| Return visit (30+ min) | 110 | $24,178 | $117 |
| Short return visit (20+ min) | 87 | $17,755 | $83 |
| Injection of drug or substance under skin or into muscle | 109 | $6,195 | $14 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 16 | $2,423 | $67 |
| Long return visit (40+ min) | 11 | $2,064 | $172 |
| Injection, zoledronic acid, 1 mg | 12 | $325 | None |
Who their Medicare patients are
155 Original Medicare patients in 2024. Average age 79 · Under 65 0% · 85 and older 30% · Women 79% · Health risk score 1.17. At or below the middle of the specialty; the typical rheumatology clinician is at 1.38.
Conditions among them: High blood pressure 75% · Coronary heart disease 25% · Heart failure 17% · Chronic kidney disease 17% · Atrial fibrillation 17% · Diabetes 16% · Cancer 15% · COPD 14% · Depression 10%.
The office billed $2,002,702, Medicare allowed $691,606 and paid $549,944; for 50,371 services of 32 kinds; $489,559 of it was for drugs given in the office and $60,385 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 155 | 50,371 | 79 | 1.17 | $2,002,702 | $549,944 |
| 2023 | 138 | 29,697 | 80 | 1.23 | $1,076,873 | $394,866 |
| 2022 | 141 | 37,817 | 81 | 1.13 | $1,194,735 | $452,345 |
| 2021 | 131 | 26,072 | 80 | 1.10 | $961,552 | $342,285 |
| 2020 | 123 | 31,230 | 79 | 1.33 | $1,037,819 | $385,413 |
| 2019 | 153 | 20,158 | 79 | 1.23 | $1,022,391 | $386,802 |
| 2018 | 144 | 18,333 | 79 | 1.24 | $905,148 | $344,760 |
| 2017 | 148 | 17,009 | 80 | 1.38 | $891,292 | $330,023 |
| 2016 | 138 | 14,962 | 80 | 1.38 | $830,162 | $292,835 |
| 2015 | 152 | 13,522 | 79 | 1.60 | $790,308 | $274,326 |
| 2014 | 176 | 9,695 | 78 | 1.56 | $575,990 | $199,545 |
| 2013 | 185 | 8,740 | 78 | 1.34 | $482,181 | $174,864 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 10 services
| Injection, denosumab, 1 mg | 92 | $155,340 | None |
| Injection, romosozumab-aqqg, 1 mg | 16 | $118,081 | None |
| Return visit (30+ min) | 82 | $18,104 | $113 |
| Short return visit (20+ min) | 95 | $12,379 | $79 |
| Injection of drug or substance under skin or into muscle | 102 | $4,034 | $14 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 11 | $2,336 | $69 |
| Long return visit (40+ min) | 11 | $2,215 | $170 |
| Telephone medical discussion with physician, 11-20 minutes | 18 | $1,555 | $71 |
| Short return visit | 17 | $1,388 | $45 |
| Injection, methylprednisolone acetate, 40 mg | 13 | $109 | None |
2022: 8 services
| Injection, romosozumab-aqqg, 1 mg | 15 | $174,032 | None |
| Injection, denosumab, 1 mg | 84 | $139,654 | None |
| Return visit (30+ min) | 83 | $21,076 | $120 |
| Short return visit (20+ min) | 90 | $14,364 | $86 |
| Injection of drug or substance under skin or into muscle | 95 | $5,100 | $14 |
| Long return visit (40+ min) | 24 | $4,312 | $172 |
| Short return visit | 22 | $3,612 | $56 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 16 | $2,992 | $73 |
2021: 9 services
| Injection, denosumab, 1 mg | 79 | $123,999 | None |
| Injection, romosozumab-aqqg, 1 mg | 12 | $51,348 | None |
| Return visit (30+ min) | 59 | $14,961 | $121 |
| Short return visit (20+ min) | 86 | $11,993 | $88 |
| Long return visit (40+ min) | 19 | $3,841 | $175 |
| Injection of drug or substance under skin or into muscle | 87 | $3,164 | $14 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 13 | $2,833 | $79 |
| Short return visit | 33 | $2,575 | $56 |
| Telephone medical discussion with physician, 11-20 minutes | 18 | $1,256 | $60 |
2020: 8 services
| Injection, denosumab, 1 mg | 67 | $85,135 | None |
| Return visit (30+ min) | 67 | $12,593 | $95 |
| Short return visit (20+ min) | 72 | $7,287 | $67 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 15 | $3,536 | $72 |
| Injection of drug or substance under skin or into muscle | 79 | $3,250 | $14 |
| Short return visit | 32 | $2,822 | $43 |
| Long return visit (40+ min) | 12 | $2,001 | $133 |
| Telephone medical discussion with physician, 11-20 minutes | 12 | $992 | $47 |
2019: 9 services
| Injection, denosumab, 1 mg | 73 | $101,522 | None |
| Return visit (30+ min) | 111 | $23,283 | $101 |
| Short return visit (20+ min) | 80 | $8,555 | $69 |
| Long return visit (40+ min) | 41 | $7,037 | $130 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 35 | $5,751 | $74 |
| Injection of drug or substance under skin or into muscle | 86 | $2,300 | $16 |
| Injection, zoledronic acid, 1 mg | 29 | $1,258 | None |
| Short return visit | 20 | $1,053 | $44 |
| Injection, methylprednisolone acetate, 40 mg | 12 | $64 | None |
2018: 10 services
| Injection, denosumab, 1 mg | 79 | $117,845 | None |
| Return visit (30+ min) | 98 | $19,337 | $101 |
| Short return visit (20+ min) | 85 | $9,044 | $67 |
| Long return visit (40+ min) | 33 | $5,881 | $128 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 27 | $4,925 | $76 |
| Injection of drug or substance under skin or into muscle | 88 | $3,130 | $21 |
| Injection, zoledronic acid, 1 mg | 18 | $911 | None |
| Short return visit | 14 | $639 | $38 |
| Administration of influenza virus vaccine | 15 | $386 | $26 |
| Influenza vaccine, quadrivalent, 0.5 ml dosage | 15 | $262 | $17 |
2017: 8 services
| Injection, denosumab, 1 mg | 84 | $105,419 | None |
| Return visit (30+ min) | 110 | $19,144 | $99 |
| Long return visit (40+ min) | 48 | $9,584 | $135 |
| Short return visit (20+ min) | 75 | $7,502 | $66 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 27 | $4,432 | $71 |
| Injection of drug or substance under skin or into muscle | 91 | $3,771 | $26 |
| Injection, zoledronic acid, 1 mg | 18 | $893 | None |
| Injection, methylprednisolone acetate, 40 mg | 11 | $76 | None |
2016: 10 services
| Injection, denosumab, 1 mg | 76 | $97,471 | None |
| Return visit (30+ min) | 89 | $17,384 | $100 |
| Short return visit (20+ min) | 78 | $7,868 | $67 |
| Long return visit (40+ min) | 41 | $6,732 | $135 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 24 | $3,700 | $71 |
| Injection of drug or substance under skin or into muscle | 84 | $3,548 | $25 |
| Injection, zoledronic acid, 1 mg | 18 | $1,397 | None |
| Short return visit | 24 | $1,081 | $42 |
| Administration of influenza virus vaccine | 18 | $570 | $32 |
| Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluvirin) | 11 | $167 | $15 |
2015: 14 services
| Injection, denosumab, 1 mg | 71 | $85,058 | None |
| Return visit (30+ min) | 89 | $14,262 | $96 |
| Short return visit (20+ min) | 100 | $11,838 | $65 |
| Long return visit (40+ min) | 35 | $4,577 | $127 |
| Pneumococcal vaccine, 13-valent | 25 | $4,126 | $159 |
| Injection of drug or substance under skin or into muscle | 80 | $3,425 | $25 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 19 | $2,965 | $71 |
| Injection, zoledronic acid, 1 mg | 11 | $1,414 | None |
| Short return visit | 27 | $1,248 | $39 |
| Aspiration and/or injection of fluid from large joint | 14 | $1,167 | $53 |
| Administration of pneumococcal vaccine | 23 | $761 | $32 |
| Administration of influenza virus vaccine | 13 | $413 | $32 |
| Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluvirin) | 13 | $191 | $15 |
| Injection, methylprednisolone acetate, 40 mg | 17 | $72 | None |
2014: 10 services
| Injection, denosumab, 1 mg | 63 | $76,172 | None |
| Return visit (30+ min) | 86 | $15,683 | $93 |
| Short return visit (20+ min) | 118 | $13,725 | $64 |
| Long return visit (40+ min) | 51 | $7,303 | $130 |
| Injection, zoledronic acid, 1 mg | 11 | $3,621 | None |
| Injection of drug or substance under skin or into muscle | 76 | $3,187 | $25 |
| Short return visit | 36 | $1,743 | $39 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 14 | $1,262 | $70 |
| Administration of influenza virus vaccine | 18 | $560 | $31 |
| Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluvirin) | 20 | $294 | $15 |
2013: 8 services
| Injection, denosumab, 1 mg | 64 | $75,196 | None |
| Return visit (30+ min) | 87 | $15,560 | $93 |
| Short return visit (20+ min) | 113 | $11,742 | $62 |
| Long return visit (40+ min) | 66 | $9,778 | $124 |
| Injection of drug or substance under skin or into muscle | 76 | $3,309 | $25 |
| Short return visit | 55 | $2,943 | $38 |
| Aspiration and/or injection of fluid from large joint | 11 | $833 | $52 |
| Injection, methylprednisolone acetate, 40 mg | 21 | $86 | None |
Drugs they prescribed that Part D paid
$101,751
Pharmacies billed $101,751 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
209 generic and fewer than 11 brand-name prescriptions · $101,751 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Humira(Cf) | 12 | $77,364 | $6,447 |
| Celecoxib | 24 | $685 | $29 |
| Hydroxychloroquine Sulfate | 12 | $403 | $34 |
| Prednisone | 51 | $382 | $7 |
| Methotrexate | 13 | $226 | $17 |
See all 6 drugs
| Humira(Cf) | 12 | $77,364 | $6,447 |
| Celecoxib | 24 | $685 | $29 |
| Hydroxychloroquine Sulfate | 12 | $403 | $34 |
| Prednisone | 51 | $382 | $7 |
| Methotrexate | 13 | $226 | $17 |
| Allopurinol | 24 | $134 | $6 |
Year by year
| 2024 | 249 | 51 | None | None | $101,751 |
| 2023 | 227 | 45 | None | 21% | $178,104 |
| 2022 | 225 | 45 | 6% (13) | None | $120,172 |
| 2021 | 246 | 46 | 7% (16) | None | $97,786 |
| 2020 | 404 | 57 | 6% (25) | None | $115,808 |
| 2019 | 458 | 61 | 6% (27) | None | $90,953 |
| 2018 | 488 | 58 | 8% (41) | 20% | $163,122 |
| 2017 | 376 | 54 | 10% (39) | 19% | $140,709 |
| 2016 | 385 | 56 | 13% (51) | None | $104,467 |
| 2015 | 518 | 71 | 16% (82) | None | $60,979 |
| 2014 | 591 | 81 | 11% (63) | 21% | $75,953 |
| 2013 | 678 | 89 | 11% (73) | 21% | $75,692 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 6 drugs
| Humira(Cf) | 13 | $97,194 | $7,476 |
| Celecoxib | 12 | $839 | $70 |
| Hydroxychloroquine Sulfate | 11 | $644 | $59 |
| Allopurinol | 16 | $277 | $17 |
| Prednisone | 36 | $244 | $7 |
| Amlodipine Besylate | 16 | $161 | $10 |
2022: 5 drugs
| Prolia | 14 | $20,838 | $1,488 |
| Allopurinol | 11 | $354 | $32 |
| Prednisone | 27 | $318 | $12 |
| Amlodipine Besylate | 19 | $231 | $12 |
| Acetaminophen-Codeine | 11 | $144 | $13 |
2021: 5 drugs
| Hydroxychloroquine Sulfate | 14 | $550 | $39 |
| Prednisone | 36 | $376 | $10 |
| Allopurinol | 14 | $359 | $26 |
| Amlodipine Besylate | 16 | $196 | $12 |
| Acetaminophen-Codeine | 12 | $143 | $12 |
2020: 9 drugs
| Tymlos | 20 | $39,719 | $1,986 |
| Prolia | 11 | $14,135 | $1,285 |
| Hydroxychloroquine Sulfate | 27 | $2,316 | $86 |
| Prednisone | 77 | $682 | $9 |
| Alendronate | 19 | $331 | $17 |
| Allopurinol | 25 | $282 | $11 |
| Methotrexate | 11 | $230 | $21 |
| Amlodipine Besylate | 33 | $200 | $6 |
| Tramadol | 12 | $36 | $3 |
2019: 12 drugs
| Tymlos | 19 | $35,686 | $1,878 |
| Prolia | 12 | $14,741 | $1,228 |
| Hydroxychloroquine Sulfate | 35 | $5,003 | $143 |
| Prednisone | 86 | $826 | $10 |
| Metoprolol | 14 | $665 | $48 |
| Losartan | 19 | $348 | $18 |
| Allopurinol | 28 | $341 | $12 |
| Gabapentin | 11 | $334 | $30 |
| Methotrexate | 17 | $229 | $13 |
| Alendronate | 21 | $214 | $10 |
| Amlodipine Besylate | 23 | $137 | $6 |
| Trazodone | 15 | $115 | $8 |
2018: 17 drugs
| Forteo | 18 | $61,327 | $3,407 |
| Prolia | 11 | $13,244 | $1,204 |
| Hydroxychloroquine Sulfate | 46 | $5,868 | $128 |
| Pradaxa | 11 | $4,628 | $421 |
| Colcrys | 12 | $2,577 | $215 |
| Metoprolol | 21 | $1,113 | $53 |
| Prednisone | 87 | $839 | $10 |
| Hydrocodone-Acetaminophen | 20 | $573 | $29 |
| Olmesartan Medoxomil | 12 | $571 | $48 |
| Azathioprine | 11 | $442 | $40 |
| Allopurinol | 34 | $403 | $12 |
| Methotrexate | 17 | $262 | $15 |
| Atorvastatin | 11 | $220 | $20 |
| Acetaminophen-Codeine | 14 | $181 | $13 |
| Amlodipine Besylate | 22 | $140 | $6 |
| Furosemide | 13 | $59 | $5 |
| Trazodone | 14 | $51 | $4 |
2017: 10 drugs
| Esbriet | 12 | $102,804 | $8,567 |
| Prolia | 11 | $11,776 | $1,071 |
| Hydroxychloroquine Sulfate | 35 | $6,515 | $186 |
| Acyclovir | 11 | $662 | $60 |
| Methotrexate | 25 | $576 | $23 |
| Prednisone | 65 | $522 | $8 |
| Hydrocodone-Acetaminophen | 29 | $404 | $14 |
| Allopurinol | 11 | $158 | $14 |
| Furosemide | 12 | $45 | $4 |
| Trazodone | 11 | $33 | $3 |
2016: 11 drugs
| Forteo | 13 | $32,116 | $2,470 |
| Hydroxychloroquine Sulfate | 32 | $5,226 | $163 |
| Celecoxib | 11 | $1,971 | $179 |
| Hydrocodone-Acetaminophen | 35 | $833 | $24 |
| Prednisone | 58 | $505 | $9 |
| Methotrexate | 18 | $501 | $28 |
| Azathioprine | 13 | $283 | $22 |
| Potassium Chloride | 11 | $251 | $23 |
| Tramadol | 14 | $189 | $13 |
| Paroxetine | 11 | $157 | $14 |
| Furosemide | 15 | $44 | $3 |
2015: 13 drugs
| Prolia | 16 | $15,254 | $953 |
| Uloric | 20 | $5,078 | $254 |
| Hydroxychloroquine Sulfate | 37 | $4,773 | $129 |
| Prednisone | 97 | $855 | $9 |
| Hydrocodone-Acetaminophen | 54 | $803 | $15 |
| Azathioprine | 20 | $524 | $26 |
| Methotrexate | 18 | $460 | $26 |
| Potassium Chloride | 12 | $390 | $32 |
| Tramadol | 23 | $247 | $11 |
| Gabapentin | 18 | $169 | $9 |
| Paroxetine | 16 | $156 | $10 |
| Alendronate | 11 | $95 | $9 |
| Amlodipine Besylate | 14 | $67 | $5 |
2014: 15 drugs
| Prolia | 16 | $13,803 | $863 |
| Colcrys | 21 | $5,181 | $247 |
| Uloric | 17 | $5,172 | $304 |
| Hydroxychloroquine Sulfate | 40 | $1,436 | $36 |
| Prednisone | 129 | $1,282 | $10 |
| Methotrexate | 21 | $757 | $36 |
| Hydrocodone-Acetaminophen | 27 | $555 | $21 |
| Tramadol | 34 | $545 | $16 |
| Azathioprine | 16 | $328 | $21 |
| Alendronate | 24 | $222 | $9 |
| Gabapentin | 16 | $208 | $13 |
| Amlodipine Besylate | 20 | $139 | $7 |
| Paroxetine | 12 | $126 | $11 |
| Bd Ultra-Fine Pen Needle | 11 | $113 | $10 |
| Citalopram Hbr | 12 | $57 | $5 |
2013: 17 drugs
| Enbrel | 11 | $26,022 | $2,366 |
| Prolia | 17 | $14,172 | $834 |
| Colcrys | 22 | $3,408 | $155 |
| Namenda | 12 | $1,630 | $136 |
| Methotrexate | 31 | $1,475 | $48 |
| Hydroxychloroquine Sulfate | 35 | $763 | $22 |
| Tramadol | 40 | $745 | $19 |
| Prednisone | 114 | $705 | $6 |
| Hydrocodone-Acetaminophen | 15 | $356 | $24 |
| Gabapentin | 13 | $264 | $20 |
| Losartan | 21 | $248 | $12 |
| Amlodipine Besylate | 36 | $244 | $7 |
| Simvastatin | 17 | $172 | $10 |
| Levothyroxine | 19 | $143 | $8 |
| Allopurinol | 14 | $111 | $8 |
| Citalopram Hbr | 16 | $87 | $5 |
| Trazodone | 14 | $60 | $4 |
Money from drug and device companies
$1,523 in 2025
| 2025 | 12 | 30 | None | $1,523 |
| 2024 | 8 | 19 | $1,680 | $2,170 |
| 2023 | 10 | 22 | None | $1,924 |
| 2022 | 8 | 16 | None | $634 |
| 2021 | 10 | 19 | None | $464 |
| 2020 | 8 | 16 | None | $465 |
| 2019 | 16 | 37 | None | $1,288 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Abbvie | Skyrizi | $462 | 8 payments
|
| Amgen | Evenity | $255 | 7 payments
|
| Janssen Biotech | Tremfya | $206 | 3 payments
|
| InSightec | Exablate | $143 | 1 payment
|
| Ucb | Bimzelx | $125 | 1 payment
|
| Mayne Pharma Commercial | Bijuva | $122 | 1 payment
|
See all 30 published payments
| Abbvie | Meals · 2025-12-20 | Rinvoq | $19 |
| Amgen | Meals · 2025-12-19 | Evenity | $20 |
| Abbvie | Meals · 2025-12-05 | Skyrizi | $21 |
| Abbvie | Meals · 2025-11-20 | Skyrizi | $122 |
| Exact Sciences | Meals · 2025-11-14 | None | $28 |
| Amgen | Meals · 2025-11-11 | Evenity | $124 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-30 | Saphnelo | $23 |
| Abbvie | Meals · 2025-10-27 | Rinvoq | $15 |
| Mallinckrodt Hospital Products | Meals · 2025-10-17 | Acthar | $26 |
| Abbvie | Meals · 2025-10-03 | Skyrizi | $21 |
| Janssen Biotech | Meals · 2025-08-29 | Tremfya | $36 |
| Janssen Biotech | Meals · 2025-08-29 | Tremfya | $34 |
| Abbvie | Meals · 2025-08-28 | None | $122 |
| InSightec | Meals · 2025-08-26 | Exablate | $143 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-08-25 | Saphnelo | $20 |
| Amgen | Meals · 2025-08-22 | Tavneos | $23 |
| Mayne Pharma Commercial | Meals · 2025-08-20 | Bijuva | $122 |
| Pfizer | Meals · 2025-08-15 | Xeljanz | $20 |
| Abbvie | Meals · 2025-08-08 | Skyrizi | $16 |
| Amgen | Meals · 2025-07-26 | Evenity | $23 |
| Exact Sciences | Meals · 2025-07-22 | The Cologuard Plus Collection Kit | $20 |
| Amgen | Meals · 2025-06-10 | Krystexxa | $19 |
| Janssen Biotech | Meals · 2025-06-04 | Tremfya | $136 |
| Lilly USA | Meals · 2025-04-24 | Kisunla | $17 |
| Abbvie | Meals · 2025-04-24 | Rinvoq | $125 |
| Amgen | Meals · 2025-04-18 | Krystexxa | $19 |
| Ucb | Meals · 2025-04-17 | Bimzelx | $125 |
| Amgen | Meals · 2025-04-11 | Tavneos | $28 |
| Aurinia Pharma U.S. | Meals · 2025-04-05 | Lupkynis | $28 |
| Pfizer | Meals · 2025-01-10 | Xeljanz | $27 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $2,170
| Janssen Biotech | Tremfya | $1,751 | 3 payments
|
| Amgen | Evenity | $193 | 8 payments
|
| AstraZeneca Pharmaceuticals LP | Saphnelo | $63 | 2 payments
|
| Pfizer | Xeljanz | $53 | 2 payments
|
| GlaxoSmithKline | Benlysta | $32 | 1 payment
|
| Abbvie | Rinvoq | $27 | 1 payment
|
| Radius Health | Tymlos | $26 | 1 payment
|
| Lilly USA | None | $26 | 1 payment
|
2023: $1,924
| US Oncology Corporate | None | $1,139 | 5 payments
|
| Amgen | Prolia | $186 | 5 payments
|
| AstraZeneca Pharmaceuticals LP | Saphnelo | $167 | 4 payments
|
| Novartis Pharmaceuticals | None | $153 | 1 payment
|
| Ucb | Cimzia | $125 | 1 payment
|
| Radius Health | Tymlos | $51 | 2 payments
|
| Aurinia Pharma U.S. | Lupkynis | $30 | 1 payment
|
| Horizon Therapeutics plc | Krystexxa | $26 | 1 payment
|
| Pfizer | Xeljanz | $25 | 1 payment
|
| Janssen Biotech | Tremfya | $20 | 1 payment
|
2022: $634
| Radius Health | Tymlos | $206 | 4 payments
|
| Sun Pharmaceutical Industries | Cequa | $195 | 1 payment
|
| Janssen Biotech | Tremfya | $68 | 3 payments
|
| Amgen | Prolia | $46 | 2 payments
|
| Genentech USA | Ocrevus | $42 | 2 payments
|
| Novartis Pharmaceuticals | Cosentyx | $40 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Saphnelo | $20 | 1 payment
|
| Abbvie | Rinvoq | $18 | 1 payment
|
2021: $464
| GlaxoSmithKline | Benlysta | $108 | 2 payments
|
| Amgen | Evenity | $77 | 4 payments
|
| Pfizer | Xeljanz | $70 | 3 payments
|
| Radius Health | Tymlos | $61 | 3 payments
|
| AbbVie | Rinvoq | $39 | 2 payments
|
| Janssen Biotech | Tremfya | $36 | 1 payment
|
| Mallinckrodt Hospital Products | Acthar | $30 | 1 payment
|
| Genzyme | Fabrazyme | $16 | 1 payment
|
| Myriad Genetic Laboratories | Myrisk | $15 | 1 payment
|
| Merck Sharp & Dohme | Renflexis | $11 | 1 payment
|
2020: $465
| Amgen | Evenity | $128 | 5 payments
|
| Allergan | None | $125 | 1 payment
|
| Mallinckrodt Hospital Products | Acthar | $68 | 3 payments
|
| Genzyme | Kevzara | $47 | 2 payments
|
| Pfizer | Xeljanz | $40 | 2 payments
|
| AbbVie | Humira | $29 | 1 payment
|
| Novartis Pharmaceuticals | Cosentyx | $15 | 1 payment
|
| Radius Health | Tymlos | $13 | 1 payment
|
2019: $1,288
| Radius Health | Tymlos | $309 | 4 payments
|
| AbbVie | Humira | $171 | 3 payments
|
| Genzyme | Kevzara | $169 | 4 payments
|
| AstraZeneca Pharmaceuticals LP | Fasenra | $125 | 1 payment
|
| Mallinckrodt Enterprises | Acthar | $96 | 4 payments
|
| Amgen | Evenity | $68 | 3 payments
|
| Ucb | Cimzia | $60 | 2 payments
|
| Horizon Therapeutics plc | Krystexxa | $52 | 2 payments
|
| Janssen Biotech | Simponi Aria | $51 | 3 payments
|
| Alexion Pharmaceuticals | Strensiq | $47 | 3 payments
|
| Novartis Pharmaceuticals | Cosentyx | $36 | 2 payments
|
| Pfizer | Inflectra | $29 | 2 payments
|
| Lilly USA | None | $25 | 1 payment
|
| Sun Pharmaceutical Industries | Ilumya | $20 | 1 payment
|
| Grifols USA | Gamunex-C | $17 | 1 payment
|
| GlaxoSmithKline | Benlysta | $15 | 1 payment
|
Professional record
- NPI
- 1316028533
- Licence
- CA A049704
- Group
- County of San Mateo
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207RR0500X (207RR0500X)
- Mailing address
- 2490 Hospital Dr Ste 102, Mountain View, CA, 94040
- NPI first listed
- 2006-10-17
- NPI last updated
- 2021-04-05
- NPI record certified
- 2021-04-05
This is when the NPI record was last certified, not a medical board exam.